retatrutide type 2 diabetes trial results 2024 2025 Test on a popular unapproved peptide have revealed a concentration double that listed on the label, prompting warnings from health professionals about "enormous" overdose risks. By national health equity reporters Caitlyn New Kind of Diabetes Drug

Absolute and Relative Contraindications Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use GLP-1 receptor agonists due to thyroid C-cell tumor risk observed in animal studies

Many healthcare providers recommend pausing or carefully reassessing semaglutide use during this time , as further slowing digestion may worsen discomfort or delay recovery

Nonetheless, published data suggest outcomes are still poor: FormBlends observed that only 32% of initial Wegovy PAs went through (68% denied) at Express Scripts in 202425 data ( [3] )

Thats because the gut-brain axis the bidirectional communication highway between your enteric nervous system and your central nervous system means that what happens in your gut doesnt stay in your gut

GGR director of content Nicole Davis, CPT, PN1-NC, told me there was a slight aftertaste, but enjoyed the flavor otherwise